Skip to main content

Safety Alerts

By
VIROLOGICAL FAILURE IN HIV PATIENTS TREATED WITH THE COMBINATION OF DIDANOSINE, LAMIVUDINE AND TENOFOVIR
The World Health Organisation (WHO) in collaboration with the European Medical Evaluation Agency (EMEA), have issued a public statement warning about the high rate of Virologic failure in HIV patients treated with a triple nucleoside/nucleotide reverse transcriptase inhibitors combination containing Didanosine, Lamivudine and Tenofovir.
The warning statement is based on the observation of a high rate of virologic failure in a clinical study of HIV-infected patients receiving a once-day triple combination containing tenofovir (Viread, TDF), lamivudine (Epivir, 3TC) and enteric coated bedlets (Videx EC, ddI EC)
In the meantime doctors are advised as precautionary measure, NOT to use Tenofovir in combination with Didanosine and Lamivudine  when considering a new treatment regimen for therapy or treatment experienced HIV patients.
Patients already on therapy with above combination should be frequently monitored with a viral load test and considered for modification of therapy at first sign of viral load increase.
The precise nature of any interaction leading to non-response is currently unknown and is being investigated.
For further information contact TFDA
COUNTERFEIT TRIPLE ARV COMBINATION PRODUCT (GINOVIR 3D)
The Tanzania Food and Drugs Authority (TFDA) has received a warning information from the World Health Organisation (WHO) on the presence of counterfeit triple antiretroviral combination product, Ginovir 3D capsules, in Cote d’Ivoire.
The label of the medicines showed that each capsule of Ginovir 3D contained Zidovudine (200 mg), Lamivudine (150 mg) and Indinavir (40 mg). Laboratory tests however, did not show the presence of Lamivudine or Indinavir; the capsules were found to contain 201 mg of Zidovudine and 40 mg of Stavudine in addition to a non-identified substance. Labels indicated that the products were manufactured by Selchi Pharmaceuticals, P. O. Box 3351, WINDHOEK, Namibia.
TFDA would like to pass this warning statement to health care providers and the public in general as precautionary measure to stay alert to the possible presence of this product in our market.
Please communicate with TFDA once you see a similar product.

Comments

Post a Comment

Popular posts from this blog

ABOUT TAPSA

By
Being the student aspiring to be health cadre delivers and service providers we are entitled responsibility to the Tanzanians and world at large as tomorrow health practitioners. Having a goal to prepare diligent health professionals ADUPS was founded in Mid August 1987 by MUCHS pharmacy students and as a result of guidance and support from IPSF, the association was officially registered on the 4th April 1990 in UDSM.  It became a full member of IPSF and APSF in August 1993 and September 2002 respectively.  ADUPS has being active for almost twenty years and her members have every reason to be proud for attaining this age. In the year-2007 MUCHS declared transformation from being a constituent College of University of Dar es Salaam to full fledged University hereby namely MUHAS. ADUPS had to transform her name and become TAPSA.  Following this expansion the association is having chapters in Colleges/Universities providing a bachelor of Pharmacy such a
2 comments
Read more

CONFERENCE PROGRAMME 10TH - 12TH JUNE

By
FRIDAY, JUNE 10(DAY 1) TIME ACTIVITY PARTICIPANT 05:00pm- Arrival of upcountry delegates Accommodation and Logistics committee Registration and Reception Registration committee SATURDAY, JUNE 11(DAY 2) TIME ACTIVITY PARTICIPANT 07:00am-08:30am Arrival to the Conference Hall All 09:00am-09:10am -Conference opening -Welcome Guest of Honor -VC MUHAS -Guest of Honor 09:10am-09:20am General introduction PST General secretary 09:10am-09:30am Theme(s) introduction -Pharmacy Week -Tapsa PST/TAPSA Speeches 09:00am-09:10am PST President Michael Kishiwa 09:10am-09:20am TAPSA President Joel Rumende 09:20am-09:30am Guest of Honor Minister MoHCDGEC 09:30am-09:40am Vote of Thanks and Recognition Chairperson Organizing Committee
Post a Comment
Read more

ADDO PROGRAM. Accredited Drug Dispensing Outlets in Tanzania

By
In the past,   duka la dawa baridi in Tanzania were authorized to sell nonprescription medicines. However, a 2001 assessment showed that many shops sold prescription drugs illegally and that the drug sellers were generally unqualified and untrained. In response, the Tanzania Food and Drugs Authority (TFDA) worked with Management Sciences for Health (MSH) to develop and launch the accredited drug dispensing outlet (ADDO) program—or   Duka la Dawa Muhimu —in 2003 in Ruvuma region. The goal of the ADDO program was to improve access to affordable, quality medicines and pharmaceutical services in areas where few or no registered pharmacies existed. The program’s primary activities include— Developing accreditation based on Ministry of Health and Social Welfare-instituted standards and regulations Creating a strong public sector-based regulatory and inspection system and strengthening local regulatory processes and capacity Developing drug shop owners’ business skills Providin
Post a Comment
Read more